Similarly, the phase I/II trial PANACEA, which tested the anti-ICM pembrolizumab combined with the TTmAb trastuzumab in patients with HER2-amplified breast cancer, showed an improved clinical benefit in the subset of patients with PD-L1-positive tumors [68]. This evidence concerns the gene ERBB2 and breast cancer.